The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer: Big Ten Cancer Research Consortium GI22-588.

Anita  Turk

Consulting or Advisory Role - Jazz Pharmaceuticals; KLM Solutions

Research Funding - Lilly (Inst); Merck (Inst)

Salma  Jabbour

Consulting or Advisory Role - Advarra; AstraZeneca; Merck Sharp & Dohme; Radialogica

Research Funding - Beigene (Inst); Guardant Health (Inst); Haystack Oncology (Inst); Merck Sharp & Dohme (Inst); NCI (Inst)

Expert Testimony - deichert

Travel, Accommodations, Expenses - AstraZeneca; Merck

Yixing  Jiang

Honoraria - Cardinal Health

Consulting or Advisory Role - Innovative cell therapy

Research Funding - white oak

Dustin  Deming

Consulting or Advisory Role - DoMoreDx; Foundation Medicine; Illumina; Inocras; Pfizer; Regeneron; Seagen; Taiho Oncology

Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Ipsen; Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)